JP2020528884A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528884A5
JP2020528884A5 JP2020502185A JP2020502185A JP2020528884A5 JP 2020528884 A5 JP2020528884 A5 JP 2020528884A5 JP 2020502185 A JP2020502185 A JP 2020502185A JP 2020502185 A JP2020502185 A JP 2020502185A JP 2020528884 A5 JP2020528884 A5 JP 2020528884A5
Authority
JP
Japan
Prior art keywords
range
composition according
compound
cancer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020502185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528884A (ja
JP7170030B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/043433 external-priority patent/WO2019023198A1/en
Publication of JP2020528884A publication Critical patent/JP2020528884A/ja
Publication of JP2020528884A5 publication Critical patent/JP2020528884A5/ja
Application granted granted Critical
Publication of JP7170030B2 publication Critical patent/JP7170030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020502185A 2017-07-25 2018-07-24 キナーゼを調節する化合物の製剤 Active JP7170030B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762536574P 2017-07-25 2017-07-25
US62/536,574 2017-07-25
PCT/US2018/043433 WO2019023198A1 (en) 2017-07-25 2018-07-24 FORMULATION OF A COMPOUND MODULATING KINASES

Publications (3)

Publication Number Publication Date
JP2020528884A JP2020528884A (ja) 2020-10-01
JP2020528884A5 true JP2020528884A5 (cg-RX-API-DMAC7.html) 2021-09-02
JP7170030B2 JP7170030B2 (ja) 2022-11-11

Family

ID=63143418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502185A Active JP7170030B2 (ja) 2017-07-25 2018-07-24 キナーゼを調節する化合物の製剤

Country Status (10)

Country Link
US (3) US10435404B2 (cg-RX-API-DMAC7.html)
EP (1) EP3658189A1 (cg-RX-API-DMAC7.html)
JP (1) JP7170030B2 (cg-RX-API-DMAC7.html)
KR (1) KR102615829B1 (cg-RX-API-DMAC7.html)
CN (1) CN110944670B (cg-RX-API-DMAC7.html)
AU (1) AU2018307910B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019028235B1 (cg-RX-API-DMAC7.html)
CA (1) CA3070505C (cg-RX-API-DMAC7.html)
TW (1) TWI805599B (cg-RX-API-DMAC7.html)
WO (1) WO2019023198A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
US10519237B2 (en) * 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN112574196A (zh) 2015-05-06 2021-03-30 普莱希科公司 调节激酶的1H-吡咯并[2,3-b]吡啶衍生物的合成
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
HK1255102A1 (zh) 2015-09-21 2019-08-02 Plexxikon Inc. 杂环化合物及其应用
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
BR112019028235B1 (pt) * 2017-07-25 2024-04-30 Plexxikon, Inc. Composições e seus métodos de preparação
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
CA3080197C (en) 2017-10-27 2023-12-19 Plexxikon Inc. Formulations of a compound modulating kinases
US11149011B2 (en) 2018-03-20 2021-10-19 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
JP7636646B2 (ja) 2019-04-09 2025-02-27 オプナ バイオ ソシエテ アノニム Ｅｐ３００またはｃｂｐの調節のための縮合アジンおよびその適応
WO2021113625A1 (en) 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
WO2021144360A1 (en) * 2020-01-17 2021-07-22 F. Hoffmann-La Roche Ag Small molecule csf-1r inhibitors in therapeutic and cosmetic uses
JP7842698B2 (ja) 2020-04-23 2026-04-08 オプナ バイオ ソシエテ アノニム Ｃｄ７３調節のための化合物及び方法並びにそれらの表示
AU2021327375A1 (en) 2020-08-21 2023-03-16 Opna Bio SA Combinational drug anticancer therapies
KR20230088761A (ko) 2020-10-13 2023-06-20 베링거 인겔하임 인터내셔날 게엠베하 재가공하는 방법
CN115925700B (zh) * 2022-11-21 2025-02-18 罗欣药业(上海)有限公司 一种酪氨酸激酶抑制剂的晶型及其制备方法
JP2026502949A (ja) 2022-12-30 2026-01-27 アヴィセンナ バイオサイエンシズ インコーポレイテッド アザインドールｒｏｃｋ阻害剤

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171062A1 (en) 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
AU2003272548A1 (en) 2002-09-16 2004-04-30 Plexxikon, Inc. Crystal structure of pim-1 kinase
US20050048573A1 (en) 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
EP1627045A2 (en) 2003-02-28 2006-02-22 Plexxikon, Inc. Pyk2 crystal structure and uses
US20050079548A1 (en) 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
BRPI0412684A (pt) 2003-07-17 2006-10-03 Plexxinko Inc compostos ppar-ativos
WO2005028624A2 (en) 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
US7517970B2 (en) 2003-12-19 2009-04-14 Plexxikon, Inc. Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
TW200616632A (en) 2004-06-17 2006-06-01 Plexxikon Inc Compounds modulating c-kit activity and uses therefor
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
CN101048407A (zh) 2004-09-03 2007-10-03 普莱希科公司 双环杂芳基pde4b抑制剂
AU2005311826A1 (en) 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR active compounds
EP1819673A2 (en) 2004-11-30 2007-08-22 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
US20060160135A1 (en) 2004-12-08 2006-07-20 Weiru Wang SF-1 and LRH-1 modulator development
AU2006272951A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CA2621275A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
CA2621474A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. 1,3-disubstituted indole derivatives for use as ppar modulators
CA2621406A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
RU2009122670A (ru) 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
CN101668737A (zh) 2007-03-08 2010-03-10 普莱希科公司 Ppar活性化合物
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
CN104530052A (zh) 2008-06-10 2015-04-22 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
AR075812A1 (es) 2009-03-11 2011-04-27 Plexxikon Inc Derivados de pirrol[2,3-b]piridina como inhibidores de raf quinasa
AR076105A1 (es) 2009-03-11 2011-05-18 Plexxikon Inc Derivados pirrol[2,3-b]piridina para inhibir la raf quinasa
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
CA2738573C (en) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
SG175877A1 (en) 2009-05-04 2011-12-29 Plexxikon Inc Compounds and methods for inhibition of renin, and indications therefor
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
EP2501236B1 (en) 2009-11-18 2017-03-29 Plexxikon Inc. N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
CA2784393A1 (en) 2009-12-23 2011-06-30 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
US8642606B2 (en) 2010-09-29 2014-02-04 Plexxikon Inc. ZAP-70 active compounds
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
CA2836474A1 (en) 2011-05-17 2012-11-22 Plexxikon Inc. Kinase modulation and indications therefor
ES2606148T3 (es) 2011-11-01 2017-03-22 Inopharm Limited Composición de disgregación oral de agentes antihistamínicos
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR20140030505A (ko) 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN105073747B (zh) 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US20160022604A1 (en) 2014-07-23 2016-01-28 Cadila Healthcare Limited Directly compressed ospemifene compositions
ES2774177T3 (es) 2014-09-15 2020-07-17 Plexxikon Inc Compuestos heterocíclicos y usos de estos
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
SMT202000535T1 (it) 2015-05-06 2020-11-10 Plexxikon Inc Forme solide di composto modulante chinasi
CN112574196A (zh) 2015-05-06 2021-03-30 普莱希科公司 调节激酶的1H-吡咯并[2,3-b]吡啶衍生物的合成
WO2016188816A1 (en) * 2015-05-22 2016-12-01 Ucb Biopharma Sprl Treatment of epilepsy
HUE050936T2 (hu) 2015-05-22 2021-01-28 Plexxikon Inc Heterociklusos vegyületek szintézise
BR112017025045A2 (pt) 2015-05-22 2018-08-07 Plexxikon Inc plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
HK1255102A1 (zh) 2015-09-21 2019-08-02 Plexxikon Inc. 杂环化合物及其应用
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10160747B2 (en) 2016-03-16 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
WO2018175311A1 (en) 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
BR112019028235B1 (pt) 2017-07-25 2024-04-30 Plexxikon, Inc. Composições e seus métodos de preparação

Similar Documents

Publication Publication Date Title
JP7170030B2 (ja) キナーゼを調節する化合物の製剤
JP2017535550A5 (cg-RX-API-DMAC7.html)
TWI845657B (zh) (s)-1-(4-氟苯基)-1-(2-(4-(6-(1-甲基-1h-吡唑-4-基)吡咯并[2,1-f][1,2,4]三嗪-4-基)哌嗪基)-嘧啶-5-基)乙-1-胺之晶形及其製造方法
KR20230041049A (ko) 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법
HRP20201383T1 (hr) Kruti oblici spoja za moduliranje kinaza
JP2018515490A5 (cg-RX-API-DMAC7.html)
JP2013536833A5 (cg-RX-API-DMAC7.html)
JP2016513704A5 (cg-RX-API-DMAC7.html)
CN111635406A (zh) 用于药物制剂中的PI3Kδ选择性抑制剂的改良形式
JP2020531463A5 (cg-RX-API-DMAC7.html)
JP2013536243A5 (cg-RX-API-DMAC7.html)
JP2022515239A5 (cg-RX-API-DMAC7.html)
JP2017507980A5 (cg-RX-API-DMAC7.html)
JP2019535715A5 (cg-RX-API-DMAC7.html)
JP2025508435A5 (cg-RX-API-DMAC7.html)
TWI653052B (zh) ［<sup></sup>Ｆ］Ｔ８０７衍生物的製備及用途
JP2023527488A (ja) ノルアドレナリン作動性および特異的セロトニン作動性抗不安薬および抗うつ薬、その生産および使用のための方法